Partial Corticotrope Insufficiency
Conditions
Keywords
neuropsychological effects of hydrocortisone replacement
Brief summary
The purpose of this study is to evaluate the efficacy of hydrocortisone replacement therapy in patients with partial cortisol deficiency after traumatic brain injury or subarachnoid hemorrhage on cognitive function.
Detailed description
This is a controlled, randomized, double-blind, placebo-controlled, crossover, interventional study. The benefit of replacement in partial corticotropic failure on brain function (cognition), especially in cases with borderline low cortisol levels after stimulation is unknown. Moreover, since glucocorticoids might affect hGH secretion, the effect of hydrocortisone on hGH secretion reflected by IGF-1 levels will be assessed. If IGF-1 is below 2 SD at the end of the study, hGH secretion will additionally be determined by a GHRH-arginine-test. An improved cognition in TBI and SAH patients with partial corticotropic insufficiency would give a new treatment option in this population which may lead to better quality of life and an enhanced rehabilitation process.
Interventions
DRUGHydrocortisone
20 mg po for 7 days (2 tablets)
DRUGPlacebo
2 tablets po
Sponsors
Novo Nordisk A/S
Max-Planck-Institute of Psychiatry
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Adult patients (male and female) between 18 and 75 years * 1 -12 month after TBI or SAH before prescreening * Cortisol level 100-180 ng/ml after stimulation with ACTH * Written informed consent by patient or a legally accepted representative
Exclusion criteria
* Pregnancy and lactation period (during study treatment) * Concomitant or previous high-dose therapy with glucocorticoids; previous treatment with glucocorticoids will be accepted, if it has been low dose (i.e. lower than the Cushing threshold) and has been stopped at least 3 months before study participation * Suspected or known hypersensitivity to hydrocortisone or any of its components * Albumine less than 2,5 g/dl * Suspected or known drug or alcohol abuse * Planned treatment for thyroid dysfunction or a planned change in established thyroid treatment * Any condition which in the opinion of the investigator makes the patient unsuitable for inclusion. * Participation in another clinical trial with investigational new drugs * Severe medical or psychiatric disease * Change of dosage of any other drug which might influence the corticotrope axis or cognitive function (e.g. antidepressive treatment) during the last 3 weeks * Oral contraceptives * Severe disturbances in articulation, visual faculty or hearing * Any elective surgery or medical treatment planned in the observation period * Intensive Care treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in score of alertness test (TAP)- interindividual differences | day -5 to - 0 (before start of study treatment), day 7 (after 7 days treatment with Hydrocortisone or Placebo, day 14 (after 7 days treatment with Hydrocortisone or Placebo) |
Secondary
| Measure | Time frame |
|---|---|
| Changes in score of Alertness Test (TAP) - intraindividual differences | day -5 to - 0 (before start of study treatment), day 7 (after 7 days treatment with Hydrocortisone or Placebo, day 14 (after 7 days treatment with Hydrocortisone or Placebo) |
Countries
Germany
Outcome results
None listed